Search company, investor...
Sema4 company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Reverse Merger | IPO

Total Raised


About Sema4

Sema4 is a patient-centered, health intelligence company dedicated to advancing the diagnosis, treatment, and prevention of disease. Sema4 uses advanced network analysis to build better models of human health and deliver personalized insights for patients.

Sema4 Headquarters Location

333 Ludlow Street North Tower, 8th floor

Stamford, Connecticut, 06902,

United States

800-298 6470

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Sema4

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sema4 in 4 CB Insights research briefs, most recently on Dec 14, 2020.

Expert Collections containing Sema4

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sema4 is included in 9 Expert Collections, including Medical Devices.


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,412 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

260 items

Latest Sema4 News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sema4 Holdings Corp. - SMFR; SMFRW

Sep 24, 2022

New York, New York--(Newsfile Corp. - September 23, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Sema4 Holdings Corp. ("Sema4" or the "Company") (NASDAQ: SMFR) (NASDAQ: SMFRW). Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 7980. The investigation concerns whether Sema4 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On July 22, 2021, CM Life Sciences, Inc., a special purpose acquisition company, completed its business combination with Mount Sinai Genomics, Inc., and the combined public entity was renamed Sema4. Less than a year later, on June 14, 2022, Sema4 announced that its Chief Financial Officer had departed. Then, on August 15, 2022, after the market closed, Sema4 announced changes to its research and development leadership team, including that its founder was stepping down from the organization and leaving his role as President and Chief R&D Officer. The Company also disclosed that it was eliminating approximately 13% of its workforce as part of a series of restructuring and corporate realignments. Additionally, Sema4 lowered its fiscal 2022 revenue guidance to $245 million to $255 million from its prior guidance of $305 million to $315 million. On this news, Sema4's stock fell $0.80, or 33.3%, to close at $1.60 per share on August 16, 2022, thereby injuring investors. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See CONTACT:

Sema4 Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sema4 Rank

  • When was Sema4 founded?

    Sema4 was founded in 2017.

  • Where is Sema4's headquarters?

    Sema4's headquarters is located at 333 Ludlow Street, Stamford.

  • What is Sema4's latest funding round?

    Sema4's latest funding round is Reverse Merger.

  • How much did Sema4 raise?

    Sema4 raised a total of $241M.

  • Who are the investors of Sema4?

    Investors of Sema4 include BlackRock, Deerfield Management, Viking Global Investors, Casdin Capital, Fidelity Investments and 15 more.

  • Who are Sema4's competitors?

    Competitors of Sema4 include Verily Life Sciences and 6 more.

You May Also Like

Protean BioDiagnostics Logo
Protean BioDiagnostics

Protean BioDiagnostics is committed to creating and deploying laboratory diagnostic tools to support physicians.

Color Logo

Color democratizes access to genetic information. The Color Test is physician-ordered and comes with complimentary board-certified genetic counseling for clients and healthcare providers. The 30-gene Color Test analyzes genes closely associated with some of the most common hereditary cancers: breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers.

Perthera Logo

Perthera uses AI to analyze patient medical and molecular data to enable hospitals, physicians & advocacy groups to deliver personalized cancer care. The Perthera Platform matches patients to ranked therapeutic options to improve their clinical outcomes and allows patient data access to the key segments in the Precision Oncology market. It was founded in 2012 and is based in McLean, Virginia.

Verana Health Logo
Verana Health

Verana Health assembles clinical databases in medicine to empower physicians and accelerate research for patients. The databases produce drug lifecycle and medical practice insights.

Owkin Logo

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology. The company was founded in 2016 and is based in New York, New York.

Mango Sciences

Mango Sciences is an emerging market data science company that connects underrepresented patients to precision medicine. The company's platform utilizes AI analytics to transform deep clinical data into key insights. It is based in Boston, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.